new
diseas
sever
atyp
respiratori
syndrom
sar
emerg
china
late
develop
first
epidem
centuri
diseas
caus
unknown
anim
coronaviru
cov
cross
speci
barrier
close
contact
human
infect
anim
identifi
etiolog
agent
sar
new
cov
becam
readili
transmiss
human
also
also
pathogen
diseas
spread
across
world
rapidli
due
air
travel
infect
peopl
caus
death
countri
contin
diseas
character
flulik
symptom
includ
high
fever
malais
cough
diarrhea
infiltr
visibl
chest
radiographi
overal
mortal
vari
profoundli
age
cours
diseas
seem
milder
pediatr
age
group
result
rare
fatal
outcom
mortal
elderli
high
aggress
quarantin
measur
taken
health
author
success
contain
termin
diseas
transmiss
result
sar
case
record
recent
nevertheless
possibl
diseas
may
emerg
popul
high
vigor
signific
progress
made
understand
diseas
biolog
pathogenesi
develop
anim
model
design
evalu
differ
vaccin
focu
chapter
new
infecti
diseas
known
sever
acut
respiratori
syndrom
sar
appear
guangdong
provinc
southern
china
character
mainli
flulik
symptom
includ
high
fever
dri
nonproduct
dyspnea
infiltr
visibl
chest
radiographi
third
case
result
pneumonia
led
acut
breath
problem
requir
artifici
respir
overal
mortal
sar
vari
greatli
age
mortal
rate
elderli
high
previous
unidentifi
coronaviru
isol
vero
cell
inocul
clinic
specimen
nasopharyng
oropharyng
sputum
sar
patient
associ
viru
diseas
confirm
monkey
inocul
viru
develop
symptom
similar
observ
human
case
sar
although
accur
inform
onset
sar
epidem
avail
chines
ministri
health
report
outbreak
unexplain
pneumonia
world
health
organ
februari
sar
associ
coronaviru
sarscov
believ
jump
anim
host
human
rural
area
guangdong
provinc
spread
rapidli
throughout
world
via
air
travel
period
novemb
juli
epidem
sar
spread
countri
affect
approxim
peopl
result
death
sever
crippl
asian
economi
overal
cost
outbreak
estim
approach
billion
mostli
result
cancel
travel
decreas
invest
affect
region
howev
aggress
quarantin
measur
success
control
emerg
sar
yet
januari
two
new
confirm
case
commun
acquir
sar
report
china
suggest
infecti
diseas
complet
elimin
may
dramat
reemerg
human
popul
base
phylogenet
analysi
replicas
gene
coronavirus
cov
divid
three
main
sero
group
group
cov
includ
transmiss
gastroenter
viru
human
cov
group
ii
cov
includ
mous
hepat
viru
bovin
cov
group
iii
includ
infecti
bronchiti
viru
fig
phylogenet
analys
complet
genom
sequenc
sarscov
suggest
close
relat
three
previous
identifi
coronaviru
group
seem
reassort
known
coronavirus
uniqu
sequenc
suggest
viru
evolv
independ
member
famili
long
period
time
search
possibl
natur
reservoir
sarscov
ongo
sinc
could
serv
launch
pad
anoth
sar
outbreak
date
effort
limit
success
viru
close
sequenc
homolog
isol
palm
civet
raccoon
dog
chines
ferret
badger
indic
viru
may
jump
recent
mammal
human
cat
may
infect
viru
spread
show
clinic
sign
infect
moreov
viru
detect
bodysurfac
gut
content
cockroach
pcr
organ
neg
might
act
mechan
vector
viru
transmiss
pandem
potenti
pathogen
sarscov
well
absenc
effect
licens
drug
highlight
need
aggress
effort
direct
toward
develop
safe
effect
vaccin
avail
prophylact
vaccin
would
particularli
desir
solut
sinc
would
prevent
diseas
vaccin
peopl
would
also
reduc
overal
spread
viru
develop
coronaviru
vaccin
gener
challeng
sever
encourag
factor
point
toward
feasibl
develop
sarscov
vaccin
evid
sarscov
induc
acut
infect
diseas
gener
complic
develop
vaccin
microorgan
induc
chronic
infect
infect
mount
strong
humor
respons
passiv
transfer
sera
obtain
convalesc
patient
sar
patient
result
reduct
viral
load
save
live
patient
rel
eas
viru
propag
vitro
proof
concept
effect
licens
veterinari
coronaviru
vaccin
base
inactiv
live
attenu
viru
includ
canin
coronaviru
avian
infecti
bronchiti
viru
chapter
focu
gene
protein
sarscov
b
correl
protect
c
anim
model
applic
differ
technolog
develop
sar
vaccin
e
use
adjuv
deliveri
system
enhanc
potenc
vaccin
f
potenti
issu
diseas
enhanc
due
vaccin
similar
coronavirus
sarscov
envelop
positivestrand
rna
viru
featur
larg
viral
genom
encod
three
differ
type
protein
known
structur
ii
nonstructur
iii
accessori
protein
discuss
differ
protein
one
one
group
protein
includ
spike
envelop
e
matrix
glycoprotein
nucleocapsid
protein
n
e
protein
incorpor
viral
envelop
sprotein
dimer
trimer
protrud
viral
membran
provid
cov
characterist
coronaresembl
shape
fig
structur
protein
focu
spike
nucleocapsid
protein
prime
target
develop
effect
efficaci
vaccin
protein
sarscov
larg
transmembran
glycoprotein
coronavirus
respons
viru
bind
fusion
entri
sinc
protein
expos
surfac
virion
major
target
induc
neutral
antibodi
furthermor
protein
play
critic
role
viral
pathogenesi
virul
also
import
viral
function
antigen
protein
type
transmembran
glycoprotein
amino
acid
cov
sprotein
contain
ntermin
signal
peptid
facilit
transport
endoplasm
reticulum
protein
extens
glycosyl
notabl
sarscov
consensu
site
nlink
glycosyl
comparison
sar
protein
protein
coronavirus
reveal
sequenc
sarscov
protein
may
follow
hypothet
featur
cleavabl
secretori
signal
ii
put
globular
domain
residu
potenti
receptor
bind
lipid
bilay
compris
spike
protein
membran
protein
envelop
protein
cloak
helic
nucleocapsid
consist
nucleocapsid
protein
associ
viral
rna
adapt
site
iii
put
stalk
domain
residu
fusion
peptid
heptad
repeat
iv
hydrophob
transmembran
tm
domain
near
c
terminu
could
respons
anchor
protein
virion
lipid
envelop
v
cysteinerich
cy
domain
immedi
follow
membran
anchor
region
featur
common
coronavirus
may
involv
stabil
proteinlipid
interact
domain
respons
viru
bind
receptor
target
cell
demonstr
angiotensinconvert
enzym
function
receptor
sarscov
investig
map
approxim
amino
acid
region
domain
amino
acid
respons
interact
receptor
amino
acid
domain
known
receptorbind
domain
rbd
domain
contain
put
fusion
peptid
two
heptad
repeat
region
upon
bind
rbd
viral
protein
target
cell
chang
conform
interact
region
form
fusogen
core
bring
viral
target
cell
membran
close
proxim
result
viru
fusion
entri
region
associ
form
sixhelix
bundl
structur
peptid
deriv
region
sarscov
protein
inhibitori
activ
sarscov
infect
indic
fragment
contain
function
domain
protein
may
use
antigen
induc
antibodi
block
viru
bind
fusion
notabl
glycoprotein
gp
highli
diverg
virus
includ
human
immunodefici
viru
hiv
mous
hepat
coronaviru
mhv
exhibit
similar
architectur
gp
refer
class
fusion
protein
use
similar
mechan
promot
membran
fusion
import
implic
therapeut
intervent
howev
despit
similar
domain
organ
sarscov
sprotein
exhibit
signific
sequenc
ident
sprotein
cov
highest
sequenc
conserv
found
heptad
repeat
hr
locat
within
region
underlin
import
function
polypeptid
nglycosyl
cotransl
endoplasm
reticulum
er
process
golgi
apparatu
glycoprotein
human
coronaviru
transmiss
gastroenter
viru
tgev
porcin
respiratori
coronaviru
felin
infecti
periton
viru
canin
coronaviru
remain
singl
glycoprotein
mous
hepat
viru
bovin
coronavirus
human
coronaviru
proteolyt
cleav
two
subunit
cellular
transport
process
earlier
studi
tgev
indic
protein
oligom
compos
three
copi
monomer
glycoprotein
quaternari
structur
report
envelop
rna
virus
demonstr
import
elicit
neutral
antibodi
hemagglutinin
ha
influenza
viru
heterodim
human
immunodefici
viru
g
protein
vesicular
stomat
viru
believ
sprotein
present
trimer
surfac
sar
cov
li
colleagu
character
four
sequenti
state
purifi
recombin
ectodomain
se
compris
ectodomain
se
monom
uncleav
se
trimer
cleav
se
trimer
dissoci
monom
trimer
rosett
lower
ph
induc
irrevers
transit
flexibl
lshape
se
monom
cloveshap
trimer
proteas
cleavag
trimer
occur
boundari
ensu
dissoci
lead
major
rearrang
trimer
format
rosett
like
repres
cluster
elong
postfus
trimer
associ
fusion
peptid
state
transit
suggest
conform
chang
mediat
viral
entri
cell
howev
sprotein
differ
conform
yet
evalu
efficaci
induc
potent
neutral
antibodi
respons
bind
viral
glycoprotein
cellular
factor
receptor
enabl
entri
enhanc
viral
infect
therefor
variou
pathogen
includ
hiv
thought
interact
factor
dendrit
cell
dc
promot
spread
within
infect
individu
bind
hiv
dc
facilit
infect
nearbi
suscept
cell
mechan
complet
understood
lectin
dcsign
dendrit
cellspecif
icamgrab
nonintegrin
relat
molecul
might
instrument
process
dcsign
express
cell
line
bind
gp
hiv
catalyz
infect
adjac
receptorposit
cell
dcsign
also
interact
sarscov
sprotein
augment
infect
retrovir
particl
bear
sprotein
envelop
observ
reflect
effici
dcmediat
sarscov
transmiss
target
cell
furthermor
addit
factor
dcsign
clearli
involv
viral
transfer
notabl
dc
permiss
viru
infect
indic
product
infect
requir
transmiss
howev
interact
sarscov
dc
could
contribut
sar
pathogenesi
attach
sarscov
dermal
dc
might
facilit
viral
spread
skin
wherea
dcsignposit
alveolar
macrophag
could
promot
sarscov
replic
lung
moreov
intern
sarscov
dc
might
provid
viru
mean
immun
escap
effort
sever
group
focus
identif
cellular
receptor
sarscov
li
et
al
report
metallopeptidas
angiotensinconvert
enzym
receptor
sarscov
use
solubl
ig
fusion
protein
immunoprecipit
experi
lysat
vero
cell
cell
type
use
isol
sarscov
subsequ
proteom
analysi
reveal
highaffin
bind
partner
inhibit
sarscov
infect
suscept
cell
use
antibodi
conjunct
observ
express
resist
cell
line
sar
cov
make
highli
suscept
sar
infect
indic
interact
protein
facilit
sarscov
infect
wong
et
al
also
identifi
sarscov
receptor
use
differ
approach
bind
studi
use
solubl
fragment
sarscov
sprotein
reveal
residu
minim
receptorbind
domain
initi
search
sprotein
residu
import
bind
point
latter
crucial
associ
howev
exact
region
contact
sprotein
remain
identifi
recent
structur
ectodomain
resolv
reveal
two
ridg
flank
catalyt
site
molecular
model
suggest
ridg
might
interact
sprotein
interestingli
bind
inhibitor
probabl
also
substrat
induc
structur
chang
within
ridg
might
interfer
bind
sprotein
detail
analysi
requir
identifi
residu
within
sprotein
critic
interact
therefor
repres
attract
target
develop
inhibitor
also
conceiv
induc
potent
antibodi
receptorbind
domain
could
attract
strategi
develop
vaccin
sar
studi
might
also
import
implic
develop
small
anim
model
thu
african
green
monkey
enabl
effici
entri
sarscov
infect
macaqu
speci
reproduc
aspect
sar
human
viral
replic
mice
less
robust
induc
diseas
therefor
import
determin
potenti
reduc
interact
sarscov
sprotein
murin
limit
viral
spread
anim
case
gener
transgen
anim
would
greater
signific
carboxypeptidas
cleav
polypeptid
renalangiotensin
system
essenti
cardiac
function
express
variou
tissu
organ
importantli
major
target
cell
sarscov
pneumocyt
express
express
cell
line
correl
permiss
sarscov
sdriven
infect
indic
play
central
role
sarscov
replic
contrast
hiv
evid
requir
coreceptor
exist
altern
receptor
sarscov
entri
certain
tissu
yet
demonstr
howev
infect
organ
lung
might
contribut
sar
pathogenesi
exampl
small
intestin
enterocyt
express
permiss
sarscov
moreov
effici
infect
renal
epitheli
cell
differ
speci
isol
viru
kidney
tissu
sar
patient
suggest
sarscov
infect
kidney
cell
might
contribut
acut
renal
failur
observ
sar
patient
infect
intestin
enterocyt
kidney
cell
could
facilit
viral
transmiss
via
fecalor
rout
viral
rna
detect
stool
sampl
sar
patient
howev
unclear
transmiss
via
fece
promot
viral
spread
outbreak
hepatocyt
sar
patient
also
infect
hepatoma
cell
line
highli
permiss
replic
sarscov
infect
hepatocyt
might
therefor
partial
account
alter
level
liverspecif
enzym
commonli
observ
sar
patient
liver
tissu
found
larg
neg
protein
express
interest
examin
whether
viral
entri
facilit
low
level
express
factor
receptor
engag
activ
fusion
machineri
viral
glycoprotein
two
way
first
bind
receptor
directli
activ
fusion
process
case
hiv
murin
leukemia
viru
mlv
glycoprotein
altern
receptor
engag
trigger
intern
viral
particl
endosom
proton
activ
glycoproteindriven
membran
fusion
influenza
hemagglutinin
vesicular
stomat
viru
gprotein
vsvg
activ
low
ph
case
sar
cov
demonstr
inhibitor
vacuolar
acidif
also
block
infect
sbear
pseudotyp
suggest
potenti
trigger
fusion
activ
sarscov
sprotein
low
ph
howev
sarscov
sdriven
celltocel
fusion
occur
absenc
low
ph
therefor
sprotein
sarscov
might
abl
mediat
membran
fusion
phdepend
independ
fashion
sever
paramet
might
control
stimulu
requir
condit
one
paramet
could
associ
subunit
sarscov
sprotein
mani
class
fusion
protein
cleav
outer
transmembran
subunit
cellular
proteas
addit
cleavag
essenti
function
glycoprotein
case
hiv
envelop
contrast
sprotein
group
cov
cleav
cleavag
sprotein
mhv
group
ii
cov
appear
celltyp
depend
requir
function
base
limit
set
data
seem
obviou
consensu
site
cellular
proteas
present
sarscov
protein
effici
cleavag
protein
report
notabl
proteas
treatment
cell
express
sprotein
result
increas
celltocel
fusion
activ
indic
cleavag
protein
might
enabl
phindepend
receptordepend
trigger
fusion
activ
work
need
clearli
demonstr
role
cellular
proteas
trigger
sprotein
driven
membran
fusion
sar
cov
two
function
element
locat
transmembran
domain
cov
sprotein
key
membran
fusion
put
fusion
peptid
two
heptad
repeat
hr
function
element
elucid
context
prototyp
class
fusion
protein
hiv
cleavag
produc
fusion
activ
form
transmembran
subunit
orient
perpendicular
viral
membran
contain
fusion
peptid
stretch
hydrophob
amino
acid
nterminu
two
hr
locat
fusion
peptid
transmembran
domain
fusion
process
fusion
peptid
insert
target
cell
membran
fold
back
onto
result
format
sixhelix
bundl
structur
trimer
dimer
conform
hr
orient
antiparallel
fashion
therebi
bring
fusion
peptid
insert
target
cell
membran
transmembran
domain
insert
viral
membran
close
contact
ultim
facilit
membran
fusion
bosch
et
al
demonstr
fusion
driven
sprotein
mhv
follow
similar
principl
howev
major
differ
compar
hiv
observ
fact
cleavag
mani
cov
sprotein
includ
sarscov
need
exert
function
suggest
protein
must
intern
fusion
peptid
similar
gprotein
vsv
computerbas
analysi
predict
potenti
fusion
peptid
nterminu
sarscov
light
observ
model
membran
fusion
illustr
previous
must
revis
sarscov
sprotein
thu
upon
exposur
low
ph
possibl
intern
fusion
peptid
coval
associ
subunit
insert
target
cell
membran
membran
fusion
driven
format
sixhelix
bundl
case
influenza
ha
low
ph
environ
trigger
irrevers
conform
chang
associ
membran
fusion
wherea
exposur
vsvg
low
ph
induc
revers
transit
fusion
activ
state
natur
phinduc
conform
chang
sarscov
sprotein
remain
determin
model
propos
accur
describ
sarscov
sdriven
membran
fusion
one
would
expect
peptid
mimick
assembl
sixhelix
bundl
peptid
would
inhibit
sarscov
smediat
membran
fusion
latter
specul
base
evid
obtain
sever
viral
class
fusion
protein
includ
mhv
sprotein
hrderiv
peptid
shown
inhibit
fusion
prevent
format
sixhelix
bundl
peptid
potent
inhibit
hiv
membran
fusion
present
lownanomolar
rang
approv
use
patient
repres
first
member
entri
inhibitor
new
class
therapeut
therefor
block
sixbundl
format
either
chemic
mean
proven
therapeut
agent
wherea
direct
antibodi
critic
element
may
repres
attract
target
develop
vaccin
sarscov
n
protein
bind
genom
rna
via
leader
sequenc
recogn
stretch
rna
serv
packag
signal
lead
format
helic
ribonucleoprotein
rnp
complex
assembl
structur
rnabind
domain
sarscov
n
protein
determin
nmr
spectroscopi
consist
fivestrand
sheet
whose
fold
unrel
rnabind
protein
author
identifi
bind
site
singlestrand
rna
ssrna
use
nmr
determin
reson
residu
perturb
addit
rna
reveal
similar
mode
interact
rnabind
protein
rnp
also
identifi
small
molecul
nmrbase
screen
bind
rnabind
domain
might
impair
function
antigen
peptid
coronaviru
n
protein
recogn
cell
surfac
infect
cell
structur
mhci
molecul
hlaa
complex
peptid
deriv
sarscov
n
protein
nonam
sarsspecif
sequenc
recent
determin
resolut
similar
mhci
molecul
show
similar
peptidebind
mode
thu
structur
add
grow
librari
mhci
structur
could
use
templat
peptidebas
vaccin
design
sarscov
replicas
gene
encod
nonstructur
protein
nsp
multipl
enzymat
function
known
predict
includ
type
enzym
common
compon
replic
machineri
plusstrand
rna
virus
rnadepend
rna
polymeras
activ
rdrp
serin
proteas
activ
mpro
papainlik
proteas
activ
helicas
activ
addit
replicas
gene
encod
protein
indic
exoribonucleas
activ
exon
homologu
endoribonucleas
activ
xendou
homologu
adenosin
diphosphateribos
activ
adrp
ribos
activ
enzym
less
common
plusstrand
rna
virus
may
therefor
relat
uniqu
properti
coronaviru
replic
transcript
final
replicas
gene
encod
anoth
nine
protein
littl
known
structur
function
nsp
implic
genet
analysi
assembl
function
replicasetranscriptas
complex
genom
sequenc
numer
sarscov
isol
determin
conserv
open
read
frame
orf
sarscov
genom
occur
order
similar
size
found
coronavirus
howev
addit
conserv
gene
sarscov
genom
contain
eight
novel
orf
end
orf
date
function
gene
remain
larg
unknown
although
absenc
genom
suggest
uniqu
function
might
advantag
sarscov
replic
assembl
virul
one
socal
accessori
protein
known
structur
studi
requir
elucid
precis
function
sar
cov
infect
human
result
develop
acut
respiratori
syndrom
patient
usual
result
mortal
therefor
one
major
question
sar
immun
system
manag
control
infect
major
patient
glycoprotein
major
structur
protein
sarscov
potenti
target
sarsspecif
humor
immun
andor
cellmedi
immun
respons
recent
studi
anim
model
demonstr
vaccin
base
protein
sarscov
seem
induc
consider
neutral
antibodi
respons
provid
protect
via
inhibit
viral
replic
challeng
live
sarscov
addit
sarscov
specif
igg
detect
week
onset
syndrom
sar
patient
persist
long
period
time
polyclon
immun
sera
convalesc
sar
patient
passiv
transfer
treat
sar
patient
outbreak
find
reveal
humor
immun
respons
therefor
play
import
role
control
clear
sarscov
infect
human
mice
moreov
protein
nativ
conform
might
suitabl
candid
vaccin
approach
inde
immun
macaqu
adenovirus
code
n
trigger
product
neutral
antibodi
provid
least
indirect
proof
sbase
vaccin
hold
promis
clearli
demonstr
antibodi
realli
involv
control
sar
cov
infect
investig
resort
use
passiv
transfer
experi
practic
administ
polyclon
immunoglobulin
isol
hyperimmun
sera
anim
human
origin
introduc
von
behr
kitasato
use
extens
prophylact
well
therapeut
set
howev
risk
relat
use
human
blood
product
make
problemat
standard
therapi
human
monoclon
antibodi
may
solut
problem
addit
use
mab
ad
advantag
use
higher
titter
higher
avid
antibodi
direct
protect
epitop
furthermor
may
also
allevi
concern
diseas
enhanc
sinc
gener
low
avid
antibodi
consid
caus
diseas
enhanc
first
human
monoclon
antibodi
mab
result
screen
human
nonimmun
singlechain
variabl
region
fragment
scfv
phage
librari
construct
b
cell
domain
sarscov
spike
protein
antibodi
high
neutral
activ
vitro
block
syncytia
format
cell
express
protein
surfac
antibodi
given
prophylact
mice
dose
therapeut
achiev
human
viral
replic
reduc
order
magnitud
longer
detect
also
employ
phage
display
technolog
screen
antibodi
librari
antibodi
reactiv
protein
ter
meulen
colleagu
isol
human
mab
belong
subclass
prophylact
administr
antibodi
ferret
anim
model
sarscov
infect
diseas
reduc
replic
sarscov
lung
infect
ferret
log
p
complet
prevent
develop
sarscov
induc
lung
patholog
p
abolish
shed
viru
pharyng
secret
traggiai
cowork
chose
b
cell
convalesc
person
identifi
human
mab
recogn
sarscov
combin
magnet
fluorescenceactiv
cell
sort
isol
memori
blymphocyt
subsequ
immort
epsteinbarr
viru
ebv
b
lymphocyt
clone
select
accord
abil
recogn
sarscov
protein
andor
neutral
viru
surprisingli
small
fraction
memori
b
cell
specif
sarscov
antigen
direct
neutral
epitop
present
spike
protein
one
human
mab
test
mous
model
vivo
neutral
activ
protect
lung
complet
upper
respiratori
tract
partial
viru
replic
given
two
day
prior
challeng
sarscov
approach
advantag
fast
complet
within
month
effici
gener
larg
number
antibodi
immedi
screen
favor
affin
epitop
specif
passiv
immun
certainli
merit
especi
come
prophylact
protect
highrisk
group
like
health
care
worker
might
also
therapeut
benefit
given
earli
onset
diseas
role
cellmedi
immun
resolut
sarscov
infect
human
still
well
understood
studi
yang
colleagu
investig
observ
memori
tcell
respons
protein
persist
year
sarscov
infect
detect
product
use
elisa
elispot
assay
flow
cytometr
analysi
demonstr
cell
involv
cellular
respons
sarscov
infect
interestingli
sarscov
sspecif
memori
cell
central
memori
cell
phenotyp
howev
major
memori
cell
reveal
effector
memori
phenotyp
thu
studi
provid
evid
sarscov
infect
human
induc
cellular
immun
respons
persist
long
period
time
data
may
argu
design
vaccin
may
effect
induc
potent
neutral
antibodi
respons
also
cellular
respons
thelper
cell
respons
well
nevertheless
work
would
need
establish
direct
correl
strong
cellular
respons
reduc
viral
load
authent
anim
model
repres
infect
human
sarscov
critic
better
understand
diseas
addit
anim
model
key
preclin
evalu
effect
vaccin
lead
clinic
evalu
effort
made
differ
group
develop
rhesu
mous
ferret
challeng
model
sarscov
infect
sarscov
infect
cynomolgu
macaqu
macaca
fasciculari
follow
intratrach
inocul
histopatholog
pattern
resembl
seen
human
die
sar
anim
analyz
day
infect
hong
kong
sarscov
isol
differ
studi
use
isol
found
mild
self
limit
respiratori
symptom
anim
lowlevel
viru
replic
day
respect
ferret
cat
mice
golden
syrian
hamster
also
success
infect
sarscov
anim
model
support
viral
replic
upper
lower
respiratori
tract
although
clinic
sign
seen
sarscov
inocul
cat
infect
ferret
hand
becam
letharg
day
post
infect
develop
lung
patholog
similar
milder
describ
infect
macaqu
infect
cat
ferret
abl
effici
transmit
viru
anim
live
close
proxim
follow
intranas
administr
sarscov
strain
urbani
viru
replic
respiratori
tract
balbc
mice
golden
syrian
hamster
kinet
viru
replic
speci
resembl
peak
day
post
infect
viru
clear
day
hamster
howev
viru
reach
higher
titer
especi
upper
respiratori
tract
anim
shed
viru
longer
time
contrast
mice
hamster
show
patholog
upper
lower
respiratori
tract
well
viremia
extrapulmonari
spread
viru
liver
spleen
neither
golden
syrian
hamster
balbc
mice
show
clinic
sign
diseas
except
age
mice
twelv
fourteen
month
old
balbc
mice
infect
sarscov
demonstr
sign
clinic
ill
character
weight
loss
hunch
ruffl
fur
slight
dehydr
resolv
day
infect
compar
young
balbc
mice
sarscov
replic
enhanc
prolong
age
mice
viru
titer
higher
lung
accompani
alveolar
damag
interstiti
pneumon
anim
model
describ
differ
human
diseas
two
import
aspect
period
infect
peak
viral
load
shorter
b
patholog
shorten
diseas
rare
progress
fatal
outcom
despit
differ
anim
model
import
use
vaccin
evalu
vaccin
efficaci
gener
measur
abil
antigen
rais
protect
immunolog
respons
b
andor
cell
exposur
pathogen
ideal
creat
antigenspecif
memori
within
immun
system
individu
protect
infect
decad
sever
veterinari
coronaviru
vaccin
current
avail
efficaci
variabl
vaccin
prevent
infecti
bronchiti
viru
ibv
infect
chicken
effect
canin
porcin
vaccin
partial
effect
felin
infecti
periton
fip
vaccin
actual
deleteri
health
anim
sever
independ
parallel
vaccin
approach
evalu
sarscov
live
attenu
inactiv
viru
ii
dna
vaccin
iii
dna
prime
boost
approach
iv
use
viral
vector
deliv
vaccin
v
recombin
subunit
vaccin
vi
use
viru
like
particl
vlp
approach
potenti
advantag
disadvantag
one
need
weigh
pro
con
technolog
select
technolog
potent
induc
protect
immun
respons
choic
inactiv
vaccin
without
question
expediti
rout
pursu
reach
clinic
evalu
stage
potenti
sarscov
vaccin
safeti
record
establish
immun
peopl
hundr
million
dose
gener
easi
manufactur
moreov
abl
induc
broad
immun
respons
antigen
determin
viru
fact
mani
group
academ
institut
industri
work
develop
inactiv
vaccin
sarscov
decemb
sinovac
biotech
announc
subject
particip
phase
human
clinic
trial
test
inactiv
sarscov
vaccin
receiv
second
last
vaccin
http
wwwnewsmedicalnet
far
advers
reaction
report
particip
good
health
recent
studi
zhou
colleagu
describ
formaldehyd
inactiv
whole
viru
vaccin
test
immunogen
safeti
protect
efficaci
rhesu
monkey
anim
immun
twice
intramuscularli
im
oneweek
interv
g
nonadjuv
vaccin
challeng
week
second
immun
none
vaccin
anim
develop
clinic
symptom
upon
viru
challeng
howev
control
group
show
minor
clinic
sign
two
week
second
immun
sarscov
specif
igg
neutral
titer
highest
g
group
anim
protect
viru
challeng
replic
viru
could
detect
lung
day
post
challeng
howev
anim
receiv
lower
dosag
partial
protect
detect
increas
concentr
almost
constant
concentr
vaccin
anim
indic
driven
immun
respons
colleagu
demonstr
sarscov
inactiv
bpl
elicit
high
titer
antibodi
immun
mice
rabbit
recogn
protein
especi
receptorbind
domain
rbd
region
antisera
immun
anim
effici
bound
rbd
block
bind
rbd
angiotensinconvert
enzym
function
receptor
suscept
cell
sarscov
sensit
quantit
singlecycl
infect
assay
use
pseudoviru
bear
sarscov
protein
investig
demonstr
mous
rabbit
antisera
significantli
inhibit
proteinmedi
viru
entri
mean
inhibitori
titer
respect
data
suggest
rbd
protein
major
neutral
determin
inactiv
sar
vaccin
induc
potent
neutral
antibodi
block
sarscov
entri
anoth
studi
bpl
inactiv
sarscov
vaccin
develop
test
immunogen
efficaci
balbc
mice
collabor
nih
anim
immun
week
g
inactiv
viru
without
adjuv
oil
squaleneinwat
emuls
approv
human
use
europ
influenza
vaccin
three
dose
adjuv
bplinactiv
sar
viru
vaccin
induc
ten
fold
higher
neutral
titer
nonadjuv
vaccin
igg
subclass
determin
indic
predomin
immun
respons
adjuv
vaccin
two
week
last
vaccin
dose
mice
challeng
intranas
nasal
turbin
lung
tissu
analyz
infecti
viru
two
day
later
complet
protect
viru
replic
observ
mice
receiv
adjuv
vaccin
neither
nasal
turbin
lung
mice
contain
recover
viru
immun
nonadjuv
vaccin
result
complet
protect
upper
respiratori
tract
signific
p
reduct
viral
titer
lower
respiratori
tract
compar
control
group
number
investig
also
evalu
whole
viru
vaccin
use
uv
bpl
formaldehyd
inact
viru
mice
rabbit
combin
differ
type
adjuv
regardless
method
combin
use
vaccin
elicit
strong
immun
respons
underscor
potenti
approach
one
major
drawback
inher
vaccin
use
inactiv
virus
high
risk
accid
product
high
amount
infecti
viru
cultiv
purifi
rais
probabl
incid
use
live
attenu
viru
strain
instead
wild
type
viru
could
minim
risk
summari
vaccin
produc
inactiv
viru
use
attenu
weak
form
viru
use
recombin
form
viral
compon
inactiv
viru
vaccin
rel
safe
revert
back
live
form
also
rel
stabl
may
even
requir
refriger
import
develop
countri
eas
mobil
outbreak
emerg
situat
howev
limit
use
inactiv
vaccin
usual
requir
sever
dose
weakli
effect
stimul
immun
respons
vaccin
prevent
hepat
exampl
inactiv
viral
vaccin
furthermor
vaccin
less
character
may
requir
special
laboratori
develop
therefor
may
even
harder
get
fda
approv
clinic
evalu
unfortun
exampl
gener
lack
character
inactiv
respiratori
syncyti
viru
caus
two
death
mani
hospit
due
diseas
enhanc
vaccin
infant
dna
vaccin
quit
power
strategi
receiv
consider
attent
due
abil
induc
humor
cellular
immun
respons
induc
immun
respons
case
even
lead
protect
variou
type
infect
influenza
malaria
sar
common
featur
dna
vaccin
synthesi
antigen
occur
intracellular
compart
allow
process
antigen
enter
mhc
class
pathway
turn
gener
cytotox
tlymphocyt
ctl
activ
high
ctl
antibodi
respons
observ
mice
inject
three
time
recombin
plasmid
vector
express
n
protein
mice
immun
plasmid
contain
protein
produc
antisarscov
igg
develop
neutral
antibodi
tcell
mediat
respons
result
sixfold
reduct
viral
titer
lung
plasmid
encod
either
region
spike
protein
elicit
antibodi
product
mice
neither
antibodi
alon
capabl
neutral
viru
howev
cooper
enabl
neutral
viru
suggest
region
spike
protein
import
hostcel
viral
entri
jin
colleagu
demonstr
humoraland
cellularmedi
specif
respons
could
induc
dna
vaccin
n
e
antigen
three
dna
construct
induc
sarscovspecif
antibodi
mice
howev
highest
antibodi
induc
n
protein
follow
e
protein
addit
cell
prolifer
dth
respons
also
success
induc
mice
vaccin
construct
result
suggest
dna
vaccin
effect
prime
specif
antisarscov
respons
appar
gener
broad
rang
thelper
bcell
memori
respons
prime
also
consist
previou
observ
protect
immun
furthermor
dna
administr
gener
lower
level
suggest
dna
vaccin
may
help
polar
type
respons
recent
zhu
et
al
demonstr
dna
construct
base
vector
could
success
induc
sarscov
n
proteinspecif
antibodi
titer
ctl
respons
kim
demonstr
vaccin
n
dna
vaccin
could
success
induc
sarscov
antigenspecif
cell
respons
distinctli
reduc
titer
recombin
vaccinia
viru
express
sarscov
n
protein
challeng
coexpress
calreticulin
crt
kda
protein
n
gene
could
enhanc
abil
protect
viral
challeng
therefor
consist
n
protein
construct
could
induc
highest
sarsspecif
igg
cell
prolifer
vivo
ctl
respons
induc
n
protein
follow
e
furthermor
highest
type
respons
base
product
also
induc
n
protein
difficult
answer
n
truli
immunogen
compar
e
increas
level
immun
respons
may
due
epitop
n
nucleocapsid
protein
sinc
contain
amino
acid
residu
e
amino
acid
respect
addit
differenti
concentr
antigen
present
kill
sarscov
prepar
could
also
contribut
differ
demonstr
sever
studi
interact
n
protein
shi
colleagu
tri
answer
two
question
n
membran
protein
express
dna
vaccin
b
express
membran
protein
affect
immun
respons
induc
n
protein
context
dna
vaccin
anim
inject
g
mixtur
dna
vaccin
encod
n
elisa
analysi
use
n
antigen
inactiv
sarscov
particl
captur
antigen
show
coinject
sarsm
could
enhanc
antibodi
respons
n
especi
subclass
lymphocyt
stimul
gml
purifi
n
antigen
cell
n
plu
n
group
increas
compar
control
group
cytokin
elisa
analysi
reveal
coinject
could
enhanc
level
product
induc
n
antigen
viru
challeng
test
conduct
bio
safeti
laboratori
brandt
vole
sarscov
model
result
indic
coimmun
n
antigen
could
reduc
mortal
patholog
chang
lung
viru
infect
mix
vaccin
immun
group
compar
singl
vaccin
group
anoth
studi
huang
et
al
also
demonstr
immun
mice
sarscov
spike
dna
vaccin
induc
antigenspecif
cellular
humor
immun
respons
cellular
immun
respons
mediat
cell
differ
form
sar
coronaviru
spike
proteinbas
vaccin
evalu
gener
neutral
antibodi
respons
sarscov
mous
model
studi
compar
six
combin
intraperiton
ip
immun
recombin
spike
polypeptid
produc
among
combin
vaccin
examin
studi
mice
prime
sarscov
human
codon
usag
optim
spike
polypeptid
dna
vaccin
boost
speptid
produc
e
coli
gener
highest
titer
neutral
antibodi
sarscov
demonstr
speptid
produc
e
coli
induc
neutral
antibodi
sarscov
infect
hand
recombin
spike
polypeptid
gener
eukaryot
system
transfect
cell
dna
vaccin
abl
elicit
high
neutral
antibodi
titer
sarscov
infect
probabl
speptid
produc
e
coli
structur
conform
compar
sprotein
produc
mammalian
express
system
studi
document
although
recombin
speptid
produc
e
coli
abl
gener
neutral
antibodi
sarscov
infect
mice
prime
spike
polypeptid
dna
vaccin
boost
speptid
e
coli
abl
gener
high
titer
neutral
antibodi
sarscov
indic
type
vaccin
use
prime
crucial
determin
type
immun
respons
develop
boost
furthermor
also
demonstr
humor
immun
respons
develop
mice
prime
spike
dna
vaccin
boost
speptid
e
coli
develop
type
immun
respons
howev
mice
immun
speptid
e
coli
alon
develop
type
respons
indic
type
immun
respons
may
essenti
gener
neutral
antibodi
sarscov
although
result
suggest
prime
dna
vaccin
boost
speptid
produc
e
coli
success
gener
neutral
antibodi
sarscov
experi
use
infect
model
evalu
protect
immun
warrant
sinc
antispik
antibodi
shown
enhanc
infect
coronavirus
cell
cultur
system
occur
sarscov
felin
infecti
periton
viru
zakhartchouk
colleagu
evalu
efficaci
dna
prime
whole
kill
sarscov
vaccin
combin
vs
vaccin
alon
clearli
demonstr
combin
vaccin
immunogen
mice
dna
vaccin
alon
higher
antibodi
respons
compar
dna
vaccin
whole
kill
viru
vaccin
alon
well
higher
cellmedi
respons
compar
dna
vaccin
alon
elicit
find
also
suggest
protein
express
transfect
cell
singl
uncleav
polypeptid
two
differenti
glycosyl
form
combin
vaccin
dna
vaccin
induc
immun
respons
two
inject
whole
kill
vaccin
induc
respons
shown
previous
aluminum
adjuv
skew
immun
respons
toward
respons
dna
vaccin
enhanc
tcell
immun
respons
immun
associ
immun
respons
thought
essenti
control
intracellular
pathogen
therefor
chang
bia
immun
respons
may
attract
featur
vaccin
combin
strategi
compar
dna
vaccin
whole
kill
viru
live
attenu
viru
deliv
vaccin
use
viral
vector
effect
induct
function
immun
respons
variou
viral
vector
recombin
adeno
associ
viru
raav
rhabdoviru
adenoviru
mva
use
deliv
gene
gene
interest
develop
sar
vaccin
section
briefli
review
variou
viral
vector
du
colleagu
use
raav
deliv
rbd
mice
investig
demonstr
singl
dose
rbdraav
vaccin
could
induc
suffici
neutral
antibodi
sarscov
infect
two
repeat
dose
vaccin
boost
neutral
antibodi
time
level
achiev
singl
dose
immun
level
antibodi
continu
increas
entir
durat
experi
month
interest
see
neutral
activ
antibodi
continu
increas
number
immun
data
suggest
rbdraav
vaccin
deliv
prolong
immun
respons
may
due
fact
gene
express
recombin
aav
goe
slow
onset
initi
take
cours
day
week
follow
persist
gene
express
mani
month
support
report
aav
may
express
foreign
gene
longterm
vivo
differ
organ
without
result
signific
toxic
howev
limit
studi
provid
inform
antibodi
respons
reach
highest
level
time
studi
end
also
longev
antibodi
respons
nevertheless
quit
clear
raav
potenti
use
deliveri
vector
addit
gener
observ
viral
deliveri
system
ie
adenoviru
vaccinia
viru
may
use
repeat
immun
either
due
preexist
antibodi
vector
induct
vector
specif
antibodi
primari
immun
vector
specif
antibodi
limit
efficaci
subsequ
immun
enhanc
immun
respons
target
gene
repeat
immun
howev
result
clearli
demonstr
case
least
raav
may
due
lower
antigen
aav
deliveri
vector
use
studi
rhabdoviru
rv
introduc
vaccin
vector
could
also
use
express
relev
sar
viru
antigen
sever
advantag
rv
suggest
suitabl
express
vector
sar
viru
protein
modular
genom
rv
organ
short
transcript
stopstart
sequenc
flank
gene
make
readili
amen
manipul
ii
rv
genom
rna
life
cycl
rv
exclus
cytoplasm
dna
recombin
revers
integr
observ
iii
stabl
incorpor
larg
multipl
foreign
gene
kb
offer
advantag
plu
strand
rna
viru
vector
iv
rv
noncytopath
infect
cell
express
high
level
foreign
protein
extend
period
time
v
rv
induc
protect
immun
respons
varieti
anim
eg
dog
mongoos
follow
immun
oral
rout
attenu
rv
target
cell
tonsil
buccal
mucosa
vi
multipl
mutat
introduc
rv
genom
complet
abolish
pathogen
rv
render
rv
vector
extrem
safe
replicationdefect
rv
produc
safe
even
complet
immunocompromis
individu
vii
sinc
rv
contain
nucleocapsid
protein
properti
superantigen
rv
vector
uniqu
vaccin
deliveri
vehicl
evalu
abil
rv
deliv
nucleocapsid
protein
envelop
spike
protein
gene
mice
singl
inocul
rvbase
vaccin
express
sarscov
protein
induc
strong
sarscovneutr
antibodi
respons
abil
rvsarscov
vector
induc
strong
immun
respons
singl
inocul
make
promis
candid
evalu
larger
anim
well
challeng
studi
determin
protect
efficaci
immun
respons
replicationdefici
human
adenoviru
type
yet
anoth
promis
vector
induc
strong
transgen
productspecif
cellular
humor
respons
howev
one
major
limit
associ
vector
presenc
neutral
antibodi
nab
therefor
zhi
colleagu
develop
chimpanze
adenoviru
vector
circumv
interfer
preexist
immun
evalu
impact
preexist
immun
human
adenoviru
efficaci
adenovirusbas
vaccin
sar
cov
efficaci
assess
intramuscular
inject
vector
mice
measur
frequenc
sarscovspecif
cell
neutral
antibodi
nab
sarscov
immunogen
vaccin
significantli
attenu
complet
abolish
preexist
nab
titer
higher
contrast
preexist
nab
minim
effect
potenc
genet
vaccin
taken
togeth
result
warrant
develop
vaccin
vector
human
trial
earli
bisht
colleagu
determin
immunogen
protein
deliv
modifi
vaccinia
ankara
mva
balbc
mous
challeng
model
follow
intranas
intramuscular
rout
immun
irrespect
rout
immun
immun
mice
induc
serum
antibodi
recogn
sar
sprotein
elisa
also
neutral
sarscov
vitro
moreov
mva
administ
either
rout
elicit
protect
immun
shown
reduc
titer
sarscov
upper
lower
respiratori
tract
mice
challeng
passiv
transfer
serum
mice
immun
mva
naiv
mice
also
reduc
replic
sarscov
respiratori
tract
challeng
demonstr
role
anti
antibodi
protect
attenu
natur
mva
abil
mva
induc
neutral
antibodi
protect
mice
support
develop
candid
vaccin
recent
ba
colleagu
perform
head
head
comparison
differ
deliveri
technolog
dna
mva
fulllength
sarscov
gene
either
alon
combin
report
elicit
highest
level
nab
sarspseudoviru
mva
induc
tenfold
lower
level
nab
dna
lowest
therefor
live
vector
may
offer
advantag
induc
highest
level
nab
respons
one
immun
boost
dna
primeddna
boost
anim
induc
lowest
level
nab
activ
hand
prime
mva
boost
induc
highest
level
antibodi
respons
protein
interest
observ
mice
prime
mva
dna
boost
mva
induc
rel
lower
level
antibodi
compar
anim
prime
mva
boost
surprisingli
mice
prime
boost
either
mva
aa
induc
antibodi
higher
observ
follow
dna
prime
dna
boost
regimen
lower
combin
find
indic
import
heterolog
mva
prime
boost
regimen
induc
substanti
level
nab
respons
use
regimen
may
offer
altern
approach
overcom
problem
associ
limit
use
live
viral
vector
multipl
immun
due
preexist
immun
vector
ishii
et
al
construct
seri
recombin
di
rdi
highli
attenu
vaccinia
strain
highli
restrict
host
rang
mutant
vaccinia
viru
isol
success
egg
passag
die
vaccinia
strain
express
gene
encod
four
structur
protein
e
n
sarscov
rdi
elicit
sarscovspecif
serum
igg
antibodi
tcell
respons
vaccin
mice
follow
intranas
subcutan
administr
mice
subcutan
vaccin
rdi
express
protein
without
structur
protein
induc
high
level
serum
neutral
igg
antibodi
demonstr
mark
protect
immun
sarscov
challeng
absenc
mucos
iga
respons
result
indic
potent
immun
respons
elicit
subcutan
inject
rdi
contain
abl
control
mucos
infect
sarscov
thu
replicationdefici
di
construct
hold
promis
develop
safe
potent
sar
vaccin
sidestep
problem
link
risk
inactiv
sarscov
vaccin
product
recombin
subunit
vaccin
base
spike
protein
also
differ
sarscov
protein
could
design
protein
alreadi
shown
major
antigen
site
viru
antibodi
direct
protein
effici
block
sarscov
infect
vitro
vivo
protein
express
purifi
fulllength
form
cell
membran
anchor
trimer
truncat
protein
lack
transmembran
region
supernat
transfect
cell
use
baculoviru
express
protein
colleagu
character
antigen
structur
protein
panel
monoclon
antibodi
mab
isol
immun
mice
epitop
anti
mab
local
within
domain
remain
mab
map
domain
among
mab
mab
target
ntermin
region
amino
acid
aa
mab
recogn
receptorbind
domain
rbd
aa
mab
react
ctermin
region
domain
contain
major
immunodomin
site
aa
strikingli
rbdspecif
mab
potent
neutral
activ
effici
block
receptor
bind
confirm
rbd
contain
main
neutral
epitop
blockag
receptor
associ
major
mechan
sarscov
neutral
five
mab
specif
ntermin
region
exhibit
moder
neutral
activ
none
mab
react
domain
major
immunodomin
site
show
neutral
activ
neutral
mab
recogn
conform
epitop
panel
anti
mab
use
tool
studi
structur
function
sarscov
protein
bisht
colleagu
express
truncat
version
protein
amino
acid
residu
baculoviru
system
purifi
protein
homogen
evalu
mice
abil
induc
protect
antibodi
respons
truncat
form
sprotein
elicit
higher
level
neutral
antibodi
mice
protect
viral
challeng
anoth
studi
colleagu
express
fulllength
protein
fl
extracellular
domain
ec
baculovirus
compar
immunogen
mice
immun
mice
develop
high
titer
anti
antibodi
potent
neutral
activ
sar
pseudovirus
construct
protein
divers
heterolog
isol
repres
strain
human
sarscov
palm
civet
sarscov
respect
data
suggest
recombin
baculovirusexpress
protein
vaccin
possess
import
conform
neutral
epitop
import
protect
challeng
infect
demonstr
recombin
sprotein
acid
receptorbind
domain
residu
fuse
frame
human
fc
fragment
induc
highli
potent
antibodi
respons
immun
rabbit
antibodi
recogn
rbd
domain
complet
inhibit
sarscov
infect
serum
dilut
rabbit
antisera
effect
block
bind
contain
rbd
suggest
rbd
induc
highli
potent
neutral
antibodi
respons
potenti
develop
effect
safe
subunit
vaccin
prevent
sar
map
precis
epitop
rbd
colleagu
immun
mice
fc
recombin
protein
fc
induc
high
titer
rbdspecif
ab
immun
mice
sera
effect
neutral
infect
sarscov
sar
pseudovirus
develop
seri
mab
character
neutral
determin
rbd
protein
six
group
conformationdepend
epitop
design
conf
ivi
two
adjac
linear
epitop
identifi
elisa
bind
competit
assay
conf
iv
conf
v
mab
significantli
block
rbdfc
bind
angiotensinconvert
enzym
suggest
epitop
overlap
receptorbind
site
protein
mab
recogn
conform
epitop
possess
potent
neutral
activ
sar
pseudoviru
neutral
activ
dose
rang
ugml
therefor
rbd
sar
protein
contain
multipl
conform
epitop
capabl
induc
potent
nab
respons
import
target
site
develop
vaccin
immunotherapeut
interest
note
protein
produc
baculo
viru
induc
potent
bind
neutral
antibodi
mice
rabbit
howev
shown
bai
colleagu
protein
express
e
coli
fail
induc
nab
mice
clear
reason
could
one
potenti
differ
protein
produc
e
coli
baculoviru
baculoviru
produc
protein
glycosyl
e
coli
produc
protein
nonglycosyl
howev
work
need
defin
sugar
directli
involv
creat
immunodomin
epitop
sugar
involv
produc
correctli
fold
sprotein
either
situat
perhap
express
sprotein
mammalian
express
system
desir
proof
concept
studi
chang
et
al
studi
effect
intron
exon
splice
enhanc
improv
express
kda
carri
three
fragment
mammalian
cell
investig
demonstr
addit
basepair
intron
increas
express
protein
vero
cell
cho
cell
respect
furthermor
exonspl
enhanc
also
increas
express
fold
howev
combin
intron
exon
splice
enhanc
result
suppress
express
result
provid
optim
strategi
enhanc
sarscov
protein
express
mammalian
cell
may
contribut
develop
sarscov
subunit
vaccin
base
data
review
quit
evid
full
length
truncat
also
receptor
bind
domain
protein
induc
strong
bind
neutral
antibodi
respons
sprotein
mice
rabbit
furthermor
upon
challeng
pathogen
sar
viru
anim
protect
howev
clear
protein
alon
abl
induc
long
last
immun
viru
protein
n
need
includ
effect
vaccin
sar
subunit
vaccin
base
recombin
protein
suffer
poor
immunogen
owe
incorrect
fold
target
protein
poor
present
immun
system
viruslik
particl
vlp
repres
specif
class
recombin
vaccin
mimic
outer
structur
authent
viru
particl
caus
product
infect
sinc
lack
viral
genom
yet
recogn
readili
immun
system
present
viral
antigen
authent
nearauthent
conform
coexpress
mous
hepat
viru
mhv
e
protein
result
assembl
particl
protein
dispens
incorpor
present
result
secret
vlp
indistinguish
authent
virion
size
shape
n
protein
neither
requir
packag
particl
present
similar
observ
made
sarscov
e
protein
coexpress
insect
cell
use
baculoviru
express
system
whether
vlp
abl
elicit
protect
immun
respons
remain
determin
contrast
format
sarsco
vlp
mammalian
cell
seem
depend
express
e
rather
n
protein
therefor
sarsco
vlp
assembl
human
renal
epitheli
cell
reli
express
n
protein
whether
discrep
caus
differ
express
system
need
studi
vaccin
modal
may
play
crucial
role
type
antibodi
cell
respons
induc
therefor
possibl
differ
vaccin
modal
inactiv
viru
live
viru
vector
deliveri
dna
vaccin
protein
subunit
vaccin
vlp
elicit
antibodi
qualit
differ
even
immunogen
similar
addit
formul
immunogen
differ
adjuv
may
affect
matur
antibodi
respons
differ
suggest
qualit
differ
record
antibodi
respons
gener
given
antigen
formul
differ
adjuv
case
hiv
vaccin
observ
suggest
structur
specif
epitop
within
immunogen
may
present
differ
combin
differ
adjuv
therefor
even
overal
structur
immunogen
remain
stabl
exposur
specif
epitop
may
modifi
proof
concept
studi
hu
colleagu
demonstr
coinocul
dna
vaccin
induc
significantli
higher
immun
respons
compar
spike
dna
vaccin
alon
studi
evalu
rout
immun
upon
type
magnitud
immun
respons
found
oral
vaccin
evok
vigor
tcell
respons
weak
antibodi
respons
intramuscular
immun
evok
vigor
antibodi
respons
weak
tcell
respons
vaccin
electropor
evok
vigor
respons
predomin
subclass
antibodi
respons
moder
tcell
respons
enhanc
diseas
previous
immun
individu
concern
develop
vaccin
may
particularli
true
sarscov
vaccin
sinc
advers
effect
alreadi
report
one
coronaviru
vaccin
felin
infecti
periton
viru
fact
demonstr
variant
resist
antibodi
neutral
also
show
enhanc
entri
presenc
certain
antibodi
vitro
protein
differ
sarscov
strain
isol
outbreak
also
protein
viru
isol
civet
cat
use
gener
pseudo
type
virus
pseudoviru
incub
independ
immun
igg
purifi
mice
vaccin
protein
strain
urbani
inhibit
entri
demonstr
prototyp
strain
urbani
also
pseudovirus
human
isol
howev
one
pseudoviru
markedli
resist
antibodi
inhibit
polyclon
igg
unexpectedli
entri
two
pseudovirus
palm
civet
glycoprotein
markedli
enhanc
similar
effect
could
detect
human
mab
deriv
recov
sar
patient
use
instead
polyclon
igg
antibodi
insuffici
crossneutr
capac
may
enhanc
rather
protect
viru
infect
epitop
map
human
mab
use
recombin
protein
fragment
demonstr
signific
reduct
reactiv
fragment
residu
contain
substitut
sui
et
al
obtain
similar
result
test
neutral
abil
anoth
human
mab
antibodi
could
protect
mice
sarscov
strain
urbani
challeng
given
day
inocul
howev
test
vitro
abil
neutral
variou
proteinpseudo
type
virus
antibodi
bind
pseudo
type
viru
contain
substitut
spike
natur
occur
variat
protein
found
sarscov
isol
although
viru
isol
decemb
sar
patient
virus
isol
civet
cat
seem
weakli
pathogen
human
mutat
viral
genom
might
occur
impact
viral
tropism
virul
variat
viral
genom
like
continu
occur
anim
reservoir
due
high
mutat
rate
rna
virus
especi
coronavirus
addit
antibodi
mediat
viru
entri
could
function
facilit
portal
virus
gain
entranc
human
popul
sarscovlik
strain
normal
infect
hardli
infect
human
could
get
chanc
replic
thu
also
adapt
new
host
therefor
antivir
strategi
base
neutral
antibodi
whether
passiv
immunotherapi
activ
immun
care
evalu
appropri
anim
model
close
resembl
human
diseas
